Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
01 03 2020
Historique:
pubmed: 3 1 2020
medline: 15 12 2020
entrez: 3 1 2020
Statut: ppublish

Résumé

The aim of the current study was to determine patient-reported functional outcomes in men with prostate cancer (PCa) undergoing moderately hypofractionated (H-RT) or conventionally fractionated radiation therapy (C-RT) in a national cohort study. All men diagnosed with PCa between April 2014 and September 2016 in the English National Health Service undergoing C-RT or H-RT were identified in the National Prostate Cancer Audit and mailed a questionnaire at least 18 months after diagnosis. We estimated differences in patient-reported urinary, bowel, sexual, and hormonal function-Expanded Prostate Cancer Index Composite short-form 26 domain scores on a 0 to 100 scale-and health-related quality of life-EQ-5D-5L on a 0 to 1 scale-using linear regression with adjustment for patient, tumor, and treatment-related factors in addition to GI and genitourinary baseline function, with higher scores representing better outcomes. Of the 17,058 men in the cohort, 77% responded: 8,432 men received C-RT (64.2%) and 4,699 H-RT (35.8%). Men in the H-RT group were older (age ≥ 70 years: 67.5% This is the first national cohort study comparing functional outcomes after H-RT and C-RT reported by patients. These real-world results further support the use of H-RT as the standard for radiation therapy in men with nonmetastatic PCa.

Identifiants

pubmed: 31895608
doi: 10.1200/JCO.19.01538
pmc: PMC7048158
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

744-752

Subventions

Organisme : Department of Health
ID : DRF-2018-11-ST2-036
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S020470/1
Pays : United Kingdom

Références

Br J Cancer. 2018 Feb 20;118(4):489-494
pubmed: 29348490
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Urology. 2015 Jan;85(1):101-5
pubmed: 25530370
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1253-1260
pubmed: 28974414
ACR Open Rheumatol. 2019 Aug 19;1(8):493-498
pubmed: 31777830
Br J Surg. 2010 May;97(5):772-81
pubmed: 20306528
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
J Urol. 1998 Jun;159(6):1988-92
pubmed: 9598504
J Urol. 2013 Jan;189(1 Suppl):S59-65; discussion S65
pubmed: 23234635
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Lancet Oncol. 2016 Apr;17(4):464-474
pubmed: 26968359
JAMA Oncol. 2019 May 1;5(5):664-670
pubmed: 30763425
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Eur Urol Focus. 2019 Jul;5(4):577-584
pubmed: 29221876
Lancet Oncol. 2015 Dec;16(16):1605-16
pubmed: 26522334
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):555-67
pubmed: 26068490
Urology. 2010 Nov;76(5):1245-50
pubmed: 20350762
Lancet Oncol. 2019 Feb;20(2):e112-e123
pubmed: 30712798
J Public Health (Oxf). 2012 Mar;34(1):108-14
pubmed: 21745831
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):722-731
pubmed: 28244407
Cancer J. 2009 Jan-Feb;15(1):1-6
pubmed: 19197165
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):573-589
pubmed: 29280452
Radiat Oncol. 2013 Sep 04;8:206
pubmed: 24007322
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30
pubmed: 17544601
Oncotarget. 2019 Jul 16;10(44):4513-4515
pubmed: 31360300
J Clin Oncol. 2018 Jun 20;36(18):1780-1784
pubmed: 29718792
Am J Clin Oncol. 2018 Jun;41(6):558-567
pubmed: 27635624

Auteurs

Julie Nossiter (J)

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom.

Arunan Sujenthiran (A)

Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom.

Thomas E Cowling (TE)

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Matthew G Parry (MG)

Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom.

Susan C Charman (SC)

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Paul Cathcart (P)

Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Noel W Clarke (NW)

Department of Urology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Department of Urology, Salford Royal NHS Foundation Trust, Salford, United Kingdom.

Heather Payne (H)

Department of Oncology, University College London Hospitals, London, United Kingdom.

Jan van der Meulen (J)

Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Ajay Aggarwal (A)

Department of Cancer Epidemiology, Population, and Global Health, King's College London, London, United Kingdom.
Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH